Go Pro
→ Barricks gold output fell from 2 million ounces to 719000 (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.83
0.0%		$43.25
$10.11
▼
$77.20
$1.07B2.622.27 million shs490,179 shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$24.71
+3.8%		$20.23
$6.67
▼
$28.00
$1.57B1.49803,573 shs1.48 million shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.32
-0.9%		$2.25
$1.03
▼
$2.68
$1.03B1.082.89 million shs1.76 million shs
Surrozen, Inc. stock logo
SRZN
Surrozen
$23.96
+1.0%		$22.94
$10.11
▼
$35.00
$278.18M0.52283,674 shs212,866 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%+0.05%+70.77%+232.45%+626.87%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
0.00%+12.52%+20.65%+5.82%+237.11%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.00%-6.07%+3.57%+4.04%+109.01%
Surrozen, Inc. stock logo
SRZN
Surrozen
0.00%-6.48%+15.47%-14.88%+138.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$76.83
0.0%		$43.25
$10.11
▼
$77.20
$1.07B2.622.27 million shs490,179 shs
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$24.71
+3.8%		$20.23
$6.67
▼
$28.00
$1.57B1.49803,573 shs1.48 million shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.32
-0.9%		$2.25
$1.03
▼
$2.68
$1.03B1.082.89 million shs1.76 million shs
Surrozen, Inc. stock logo
SRZN
Surrozen
$23.96
+1.0%		$22.94
$10.11
▼
$35.00
$278.18M0.52283,674 shs212,866 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%+0.05%+70.77%+232.45%+626.87%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
0.00%+12.52%+20.65%+5.82%+237.11%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.00%-6.07%+3.57%+4.04%+109.01%
Surrozen, Inc. stock logo
SRZN
Surrozen
0.00%-6.48%+15.47%-14.88%+138.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.14
Hold$72.50-5.64% Downside
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2.90
Moderate Buy$51.75109.43% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.25
Hold$4.5596.12% Upside
Surrozen, Inc. stock logo
SRZN
Surrozen
2.67
Moderate Buy$42.0075.29% Upside

Current Analyst Ratings Breakdown

Latest SRZN, JBIO, FBRX, and LXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$48.00
8/10/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$45.00 ➝ $47.00
8/10/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$74.00 ➝ $77.00
8/10/2026
Surrozen, Inc. stock logo
SRZN
Surrozen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$44.00
8/3/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/28/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/28/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$74.00 ➝ $77.00
7/28/2026
Surrozen, Inc. stock logo
SRZN
Surrozen
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/27/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$77.00
7/27/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/27/2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$13.24 per shareN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/A$6.92 per shareN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$49.80M20.73N/AN/A$0.39 per share5.95
Surrozen, Inc. stock logo
SRZN
Surrozen
$3.48M79.94N/AN/A($18.83) per share-1.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$69.38M-$4.65N/AN/AN/AN/A-94.82%-77.68%N/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$127.41M-$1.92N/AN/AN/AN/A-49.11%-45.62%N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$50.34M-$0.15N/AN/AN/A-147.38%-37.53%-24.96%N/A
Surrozen, Inc. stock logo
SRZN
Surrozen
-$242.03M-$40.55N/AN/AN/A-2,885.33%N/A-93.62%N/A

Latest SRZN, JBIO, FBRX, and LXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.9950-$0.97+$0.0250-$0.97N/AN/A
8/10/2026Q2 2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$0.66-$0.76-$0.10-$0.76N/AN/A
8/6/2026Q2 2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.0502-$0.06-$0.0098-$0.07$3.99 million$0.69 million
8/6/2026Q2 2026
Surrozen, Inc. stock logo
SRZN
Surrozen
-$1.29-$0.41+$0.88-$0.41$0.47 million$5.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Surrozen, Inc. stock logo
SRZN
Surrozen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
10.01
2.75
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
14.93
14.29
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.29
13.37
13.29
Surrozen, Inc. stock logo
SRZN
Surrozen
N/A
12.14
11.91

Institutional Ownership

CompanyInstitutional Ownership
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
Surrozen, Inc. stock logo
SRZN
Surrozen
66.57%

Insider Ownership

CompanyInsider Ownership
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
4.40%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
23.06%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
14.00%
Surrozen, Inc. stock logo
SRZN
Surrozen
31.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
513.89 million13.28 millionOptionable
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2063.60 million48.93 millionN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140444.96 million382.66 millionOptionable
Surrozen, Inc. stock logo
SRZN
Surrozen
8011.61 million7.93 millionNot Optionable

Recent News About These Companies

What is HC Wainwright's Forecast for Surrozen Q3 Earnings?
August 14 at 1:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30959262
What is HC Wainwright's Estimate for Surrozen Q3 Earnings?
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-estimate-for-surrozen-q3-earnings-2026-08-12/
HC Wainwright Reaffirms Buy Rating for Surrozen (NASDAQ:SRZN)
August 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30955438
HC Wainwright Reiterates "Buy" Rating for Surrozen (NASDAQ:SRZN)
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-reiterates-buy-rating-for-surrozen-nasdaqsrzn-2026-08-10/
Surrozen (NASDAQ:SRZN) Issues Quarterly Earnings Results, Beats Expectations By $0.88 EPS
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/surrozen-nasdaqsrzn-issues-quarterly-earnings-results-beats-expectations-by-088-eps-2026-08-06/
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340707/0/en/surrozen-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Perceptive Advisors LLC Makes New $6.68 Million Investment in Surrozen, Inc. $SRZN
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-perceptive-advisors-llc-makes-new-668-million-investment-in-surrozen-inc-srzn-2026-08-02/
Surrozen, Inc. (NASDAQ:SRZN) Given Consensus Rating of "Moderate Buy" by Brokerages
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/surrozen-inc-nasdaqsrzn-given-consensus-rating-of-moderate-buy-by-brokerages-2026-07-30/
Surrozen, Inc. $SRZN Position Reduced by Stempoint Capital LP
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-surrozen-inc-srzn-position-reduced-by-stempoint-capital-lp-2026-07-30/
Surrozen (NASDAQ:SRZN) Upgraded by Zacks Research to Hold Rating
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/surrozen-nasdaqsrzn-upgraded-by-zacks-research-to-hold-rating-2026-07-30/
Surrozen (NASDAQ:SRZN) Major Shareholder Sells $6,906,250.00 in Stock
July 29, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-srzn-insider-buying-and-selling-2026-07-29/
Surrozen Inc
July 28, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/SRZN
Insider Selling: Surrozen (NASDAQ:SRZN) Major Shareholder Sells 325,000 Shares of Stock
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-surrozen-nasdaqsrzn-major-shareholder-sells-325000-shares-of-stock-2026-07-28/
Surrozen highlights Wnt retina pipeline, SZN-8141 IND timeline at HC Wainwright
July 22, 2026  |  msn.comhttps://www.msn.com/en-us/technology/tech-companies/surrozen-highlights-wnt-retina-pipeline-szn-8141-ind-timeline-at-hc-wainwright/ar-AA28tzlT
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/surrozen-highlights-wnt-retina-pipeline-szn-8141-ind-timeline-at-hc-wainwright-2026-07-22/
Surrozen to Present at Upcoming Healthcare Investor Conference
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3328105/0/en/surrozen-to-present-at-upcoming-healthcare-investor-conference.html
Surrozen (SRZN) Stock Forecast & Price Target
June 4, 2026  |  investing.comhttps://www.investing.com/equities/surrozen-consensus-estimates
We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate
May 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/were-not-very-worried-surrozens-141757978.html
Surrozen (SRZN) price target increased by 10.11% to 43.52
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/surrozen-srzn-price-target-increased-by-1011-to-4352/ar-AA23dYGu
Surrozen Shareholders Support Board, Auditor and Pay Policies
May 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/surrozen-shareholders-support-board-auditor-and-pay-policies?utm_source=marketbeat.com&utm_medium=referral
Surrozen to Present at Upcoming Healthcare Investor Conference
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3293369/0/en/surrozen-to-present-at-upcoming-healthcare-investor-conference.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$76.83 -0.03 (-0.04%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$76.85 +0.02 (+0.03%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Jade Biosciences stock logo

Jade Biosciences NASDAQ:JBIO

$24.71 +0.90 (+3.78%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$24.72 +0.00 (+0.02%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.32 -0.02 (-0.85%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$2.34 +0.02 (+0.65%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Surrozen stock logo

Surrozen NASDAQ:SRZN

$23.96 +0.23 (+0.97%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$23.92 -0.05 (-0.19%)
As of 08/14/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas